Loading clinical trials...

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease | Clinical Trials | Clareo Health

UNKNOWNPHASE2

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

NCT05194163•Neurokine Therapeutics

Summary

This study is a phase 2a randomized double-blind, placebo-controlled, study, in mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK kinase inhibitor. The primary goals of this study are to investigate the safety and tolerability, and drug movements in the body. The secondary goals of the study are to investigate the effects of the drug on cognitive performance, activities of daily living, and behavior, and the biological effects of the drug on blood biomarkers.

Eligibility

Age

50 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent from subject (or legally authorized representative, LAR) and study partner.
•2. Male or female, age 50 to 90 inclusive.
•3. Have a study partner who is able to accompany the subject, has frequent contact with subject.
•4. Meet criteria for Alzheimer's Disease by NIAA-AA criteria.
•5. Must speak English fluently.
•6. Must have education of at least 8 years.
•7. Must have adequate hearing and visual abilities.
•8. MMSE score of 14 to 28.
•9. Clinical Dementia Rating (CDR) Global score of 0.5 to 2.0 inclusive.
•10. Absence of suicidal ideation for at least 1 year.
+5 more criteria

Exclusion Criteria

•1. Presence of clinically significant disorders of the central nervous system other than Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus, epilepsy, demyelinating disease, brain tumors, or psychiatric disorders (such as schizophrenia, or severe affective disorders).
•2. Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical disease.
•3. Abnormal liver function tests (ALT or AST) or creatine kinase (CK) upon repeat testing.
•4. Chronic hepatitis B or C infection, indicated by positive HBSAg, or HCV-Ab with HCV RNA presence.
•5. Known history of human immunodeficiency virus (HIV) infection.
•6. Known immune disorder that has a history of requiring treatment with immunosuppressive drugs within the past 1 year.
•7. Have a drug or alcohol abuse within 12 months prior to screening.
•8. Clinically significant laboratory abnormalities at screening.
•9. Screening ECG showing repeated QTcF \> 480 msec, or other clinically significant ECG abnormalities.
•10. Clinically significant structural brain abnormalities, such as hydrocephalus or intra-axial brain tumors.
+4 more criteria

Locations (1)

Columbia University Irving Medical Center

New York, New York, United States

Key Dates

Start Date

May 1, 2022

Primary Completion Date

August 31, 2024

Completion Date

November 30, 2024

Last Updated

March 29, 2022

Enrollment

ESTIMATED participants

Conditions

Alzheimer Disease

Interventions

MW150

DRUG

Placebo

DRUG

Contacts

Lawrence S Honig, MD PhD

CONTACT

2123059194 lh456@cumc.columbia.edu

Wayne P Anderson, PhD

CONTACT

nkt.wanderson@gmail.com

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease